You are here


A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
Recruitment period: 
1 August 2007
Trial period: 
1 August 2007 to 1 December 2013
Clinical Trial reference link: 



The purpose of this clinical research study is to compare the rate of confirmed complete cytogenetic response (CCyR) of dasatinib to imatinib therapy within 12 months after randomization in newly diagnosed chronic phase Philadelphia positive chronic myeloid leukemia (Ph+ CML) patients. The safety of this treatment will also be studied.